Okay, Allen, you make me do my homework. Regarding the issues below, this is from Medscape: Go to one of Thomas AM Kramer's CME articles at medscape such as: http://www.medscape.com/viewarticle/420839
Then click on "disclosures" at the top of the page. You will find the following. Disclosure: Thomas Kramer, MD, has disclosed that he receives funding for clinical grants from Pfizer, Eli Lilly, Abbott, and Janssen. He holds consulting agreements with Pfizer, Eli Lilly, Glaxo, and Wyeth-Ayerst. . Now I am no longer just highly suspicious that he is well funded by the drug companies, I "am sure". Still, thanks for making me provide the evidence for my conjectures. Bill Scott ----- Original Message ----- From: "Allen Esterson" <[EMAIL PROTECTED]> To: "Teaching in the Psychological Sciences" <[EMAIL PROTECTED]> Sent: Sunday, April 25, 2004 5:50 AM Subject: Re: Suicide / Antidepressant > On 24 April I wrote, quoting Bill Scott first: > > > On April 22 Bill Scott wrote: > > > > > Dr. Kramer is a well known advocate of polypharmacy, the giving of multiple > > > drugs to alleviate disorders when single drugs have not been effective. I > > > have not looked up his connections to the drug companies but I am sure he is > > > well funded by them. His disclaimer as to funding relates only to this > > > particular message within which he reports no specific results of research. > > > I invite anyone to inform me if I am wrong. > > > > Maybe I'm missing something, but if Bill has not looked up Dr Thomas > > Kramer's connections to any drug companies, on what grounds can he be > > "sure" that Kramer is well funded by them? > > Bill Scott replied: > > > I apologize for "being sure". I strongly suspect. I should look for the > > evidence before being sure. Perhaps, if I can find the time, I will do so > > and report back. Thanks for the correction. > > > > Bill Scott > > I've checked out a number of articles by Thomas A. M. Kramer, who is > Clinical Associate Professor of Psychiatry, Northwestern University, > Chicago. A message he posted on the AAMC REPORTER website may be of > interest: > > Association of American Medical Colleges REPORTER > http://www.aamc.org/newsroom/reporter/july01/respond.htm > > Q. Should there be systems in place to educate students and residents on > appropriate interactions with pharmaceuticals? If so, what should they be? > > I think such education would be very helpful to medical trainees. It > should put these companies marketing efforts in context: how much money is > at stake, what their options are (i.e., what they can and cannot say or > do), and what they hope to accomplish. Pharmaceutical representatives > often encourage physicians and trainees to think of their companies as > benevolent "foundations," and they are anything but. This must be made > clear early in medical education. > > Thomas A.M. Kramer, M.D. > Senior Vice President > American Board of Psychiatry and Neurology Inc. > > See also: > Practitioners and the Pharmaceutical Industry > http://consultapsi.com/noticias/medicos_laborat.htm > > Allen Esterson > Former lecturer, Science Department > Southwark College, London > [EMAIL PROTECTED] > > http://www.human-nature.com/esterson/index.html > http://www.butterfliesandwheels.com/articleprint.php?num=10 > > --- > You are currently subscribed to tips as: [EMAIL PROTECTED] > To unsubscribe send a blank email to [EMAIL PROTECTED] --- You are currently subscribed to tips as: [EMAIL PROTECTED] To unsubscribe send a blank email to [EMAIL PROTECTED]
